Relationship between myocardial flow reserve by oxygen-15 water positron emission tomography in the subacute phase of myocardial infarction and left ventricular remodeling in the chronic phase

Hypertension Research

Volumn 31, Issue 7, 2008, Pages 1307-1313

  Ohara, Minako ^a   Yukiiri, Kazushi ^a   Masugata, Hisashi ^a   Iwado, Yasuyoshi ^a   Takinami, Hiroyuki ^a   Nishiyama, Yoshihiro ^a   Ohkawa, Motoomi ^a   Senda, Shoichi ^a   Ohmori, Koji ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Acute myocardial infarction; Myocardial flow reserve; Positron emission tomography; Remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXYGEN 15; SPIRONOLACTONE; WATER;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; COUGHING; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VOLUME; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE VENTRICULOGRAPHY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY CIRCULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 55449128520     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1307     Document Type: Article

References (22)

1. Yoshiyama M, Kamimori K, Shimada Y, et al: Left ventricular remodeling after myocardial infarction in antecedent hypertensive patients. Hypertens Res 2005; 28: 293-299.
2. Urabe A, Izumi T, Abe Y, Taniguchi I, Mochizuki S: Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. Hypertens Res 2006; 29: 627-634.
3. Takeda M, Tatsumi T, Matsunaga S, et al: Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 2007; 30: 427-437.
4. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trails. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97: 2202-2212.
5. Bonarjee VV, Carstensen S, Caidahl K, Nilsen DW, Edner M, Berning J: Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. Am J Cardiol 1993; 72: 1004-1009.
6. Swedberg K, Held P, Kjekshus J, Ramussen K, Ryden L, Wedel H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-684.
7. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality patient with left ventricular dysfunction after myocardial infarction; results of the ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
8. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trail. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
9. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
10. Suzuki H, Kusuyama T, Omori Y, et al: Inhibitory effect of candesalrtan cilexetil on left ventricular remodeling after myocardial infarction. Int Heart J 2006; 47: 715-725.
11. Shimada Y, Yoshiyama M, Tanaka H, et al: Convalescent stage coronary flow reserve and late myocardial morphologic outcome in patients with first anterior acute myocaerial infarction. Circ J 2004; 68: 208-213.
12. Ueno Y, Nakamura Y, Kinoshita M, Fujita T, Sakamoto T, Okamura H: Can coronary flow velocity reserve determined by transthoracic Doppler echocardiography predict the recovery of regional left ventricular function in patients with acute myocardial infarction? Heart 2002; 88: 137-141.
13. Montisci R, Chen L, Ruscazio M, et al: Non-invasive coronary flow reserve is correlated with microvascular integrity and myocardial viability after primary angioplasty in acute myocardial infarction. Heart 2006; 92: 1113-1118.
14. 15O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988; 78: 104-115.
15. Iida H, Takahashi A, Tamira Y, Ono Y, Lammertsma AA: Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation. J Nucl Med 1995; 36: 78-85.
16. 15O-water and PET using the basis function method. J Nucl Med 2005; 46: 1219-1224.
17. Miyagawa M, Kumano S, Sekiya M, et al: Thallium-201 myocardial tomography with intravenous infusion of adenosine triphosphate in diagnosis of coronary artery disease. J Am Coll Cardiol 1995; 26: 1196-1201.
18. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
19. 2O positron emission tomography. Int J Angiol 2005; 14: 133-137.
20. Drexler H, Hayoz D, Munzel T, et al: Endothelial function in chronic heart failure. Am J Cardiol 1992; 69: 1596-1601.
21. Maseri A, Crea F, Cianflone D: Myocardial ischemia caused by distal coronary vasoconstriction. Am J Cardiol 1992; 70: 1602-1605.
22. Richer C, Gervais M, Fornes P, Giudicelli JF: Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats. J Cardiovasc Pharmacol 1999; 34: 772-781.